SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-23-002306
Filing Date
2023-11-09
Accepted
2023-11-09 16:31:10
Documents
49
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q enzn-20230930x10q.htm   iXBRL 10-Q 763593
2 EX-31.1 enzn-20230930xex31d1.htm EX-31.1 14528
3 EX-32.1 enzn-20230930xex32d1.htm EX-32.1 6466
  Complete submission text file 0001410578-23-002306.txt   3149234

Data Files

Seq Description Document Type Size
4 EX-101.SCH enzn-20230930.xsd EX-101.SCH 29949
5 EX-101.CAL enzn-20230930_cal.xml EX-101.CAL 19501
6 EX-101.DEF enzn-20230930_def.xml EX-101.DEF 102756
7 EX-101.LAB enzn-20230930_lab.xml EX-101.LAB 221570
8 EX-101.PRE enzn-20230930_pre.xml EX-101.PRE 174716
43 EXTRACTED XBRL INSTANCE DOCUMENT enzn-20230930x10q_htm.xml XML 328550
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Filer) CIK: 0000727510 (see all company filings)

IRS No.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-12957 | Film No.: 231393108
SIC: 2836 Biological Products, (No Diagnostic Substances)